1 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Moffitt Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; Mayo Clinic Cancer Center; University of Michigan Rogel Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; Dana-Farber/Brigham and Women's Cancer Center; National Blood Clot Alliance; Massachusetts General Hospital Cancer Center; The University of Texas MD Anderson Cancer Center; Fred & Pamela Buffett Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; Yale Cancer Center/Smilow Cancer Hospital; Stanford Cancer Institute; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Colorado Cancer Center; Fox Chase Cancer Center; Vanderbilt-Ingram Cancer Center; Duke Cancer Institute; Roswell Park Comprehensive Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; UC San Diego Moores Cancer Center; City of Hope National Medical Center; Huntsman Cancer Institute at the University of Utah; Memorial Sloan Kettering Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; University of Wisconsin Carbone Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; and National Comprehensive Cancer Network.
Venous thromboembolism (VTE) is common in patients with cancer and increases morbidity and mortality. VTE prevention and treatment are more complex in patients with cancer. The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline strategies for treatment and prevention of VTE in adult patients diagnosed with cancer or in whom cancer is clinically suspected. These NCCN Guidelines Insights explain recent changes in anticoagulants recommended for the treatment of cancer-associated VTE.
Provided content development and/or authorship assistance.